🚀 Mission View: A sharper perspective on this week's top issues that matter at the intersection of health and AI.
And we’re back. I hope everyone had a restful holiday season.
The biggest development at the intersection of health and AI this week was OpenAI’s release of its white paper, AI as a Healthcare Ally, alongside news of an upcoming feature dubbed ChatGPT Health.
The toplines are telling. According to OpenAI, nearly 2 million ChatGPT messages each week focus on health insurance, from comparing plans and understanding prices to handling claims, billing, and enrollment. Users in rural communities send roughly 600,000 healthcare-related messages per week, and seven in ten health conversations happen outside normal clinic hours. In other words, people are already using AI to navigate the health system, whether institutions planned for it or not. Though, TBH, it does seem like OpenAI has been preparing for it for some time.
The white paper makes clear that OpenAI is not just observing this behavior. It is actively pushing for policy changes it believes are necessary to scale AI in healthcare, including reforms to how the FDA regulates certain AI-enabled medical devices. That matters, especially in light of recent moves by regulators to ease oversight (more on that below).
Turning to ChatGPT Health, OpenAI says the feature will allow users to securely connect medical records and wellness apps, including Apple Health and MyFitnessPal, so ChatGPT can help interpret test results, prepare for appointments, understand health patterns, and navigate insurance tradeoffs. The company is explicit that the tool is meant to support, not replace, medical care, and is not intended for diagnosis or treatment. It also emphasizes additional privacy and security safeguards.
Access is limited for now. Users must join a waitlist and explain their intended use. I’ve signed up and will report back once I’ve had hands-on time with it.
None of this is surprising - though you might not know it, given the amount of attention these developments received this week. Of course, I’m piling on by writing about it here. But at the end of last year, Microsoft released its own research showing widespread and growing use of AI for health-related questions, especially on mobile devices. So, the trend has been increasingly clear IMO.
What’s different now is that OpenAI is pairing real-world usage data with health-specific features and an explicit regulatory agenda. This is no longer just about general-purpose models being repurposed by health consumers. It’s about AI companies designing for healthcare directly, while simultaneously advocating for changes to the rules that govern how those tools can be deployed.
That combination, product plus policy, is what makes this moment worth paying attention to.
🛜 Field Signals: A quick hit on this week’s industry announcements, policy developments, and ethical considerations.
🏗️ Industry
AI is becoming the default starting point for daily tasks
More than 60% of consumers now begin everyday tasks with AI, according to PYMNTS. The shift from occasional use to habitual behavior helps explain why AI is increasingly shaping decisions in healthcare, insurance, and personal finance.
Hospitals are exposing both AI’s promise and its limits
Hospitals are emerging as a proving ground for what AI can and cannot do, reports The Wall Street Journal. Tools show value in documentation and workflow support, but results are mixed once they collide with legacy systems and clinical trust.
Utah becomes the first state to allow AI to prescribe drugs
Utah has become the first state to permit AI systems to autonomously renew prescriptions for certain chronic conditions. Through a partnership with Doctronic, AI can now renew prescriptions across 190 eligible medications. In testing, the system matched physician recommendations 99.2% of the time.
OpenAI and Bain outline how AI can help break through pharma’s innovation logjam
A new white paper from OpenAI and Bain & Company makes the case that AI can meaningfully accelerate pharmaceutical R&D, particularly in target discovery, trial design, and operational execution. The follow-on question, IMO (which I’ve posed before), is how any efficiencies gained in drug development accrue to consumers and payers?
The chatbot market is fragmenting
New Similarweb data shows Gemini surpassing 20% global share, Grok climbing past 3%, and ChatGPT dipping below 65%. The takeaway isn’t decline, but diversification driven by defaults, distribution, and embedded assistants.
Source: Similarweb
🏛️ Government and Policy
FDA pulls back oversight of some AI-enabled devices
The FDA is easing oversight for certain AI-enabled medical devices and wearables, according to STAT. The move aligns with industry recommendations, including from OpenAI, that current regulatory frameworks are too slow for rapidly evolving AI tools.
😇 Ethics and Responsible Use
Cheaper AI chips are coming
Nvidia’s newly announced AI chips promise far greater efficiency and dramatically lower costs, enabling faster and cheaper deployment at scale. As AI becomes more affordable and energy-efficient, it may address some of the biggest ethical quandaries facing the industry to date.
Note, Nvidia is not the only game in town attempting to develop and deploy more energy-efficient computing power. Last year, I wrote about a research team from the University of Edinburgh that developed WaferLLM, a breakthrough software system that enables large language models to run up to ten times faster. The researchers claimed the system dramatically improves speed and energy efficiency, paving the way for real-time AI in healthcare, finance, and scientific discovery.
🔬Research and Evidence
AI turns sleep into a long-term health early-warning signal
Researchers at Stanford have published SleepFM, an AI model that can predict more than 130 health conditions from a single overnight sleep recording. Trained on 600,000 hours of data and linked to decades of clinical records, the study suggests sleep data could become a powerful early-warning layer as wearables improve.
Health Affairs puts AI at the center of health policy research
The January issue of Health Affairs is out, featuring multiple articles on artificial intelligence, health spending, and system performance.
🛠️ Practical Edge: Actionable tips, tools, and thoughts to help leaders strengthen capacity and apply AI in their work.
Amazon turns Alexa into a browser-based AI copilot
Amazon has launched Alexa.com, extending its AI assistant beyond devices and into the browser. The lesson is not Alexa versus ChatGPT. It’s that adoption follows workflow gravity, not model benchmarks.
AI is moving off screens and into physical workflows
From OpenAI’s rumored AI pen to Boston Dynamics’ Atlas robot and Meta’s EMG wristband, AI is increasingly embedded into voice, gesture, and physical action. The next adoption wave will be driven as much by form factor as by model capability.
(See also: Atlas demo at CES)
A small but useful win: automatic file naming with AI
AI Renamer analyzes files and automatically assigns clear, descriptive filenames. A reminder that some of AI’s most immediate value comes from quietly removing everyday friction.
Note to my readers: I’d love to learn how you are using AI. If there’s a novel way you are deploying AI in your work, or seeing it utilized in healthcare, please feel free to shoot me a note and share: [email protected]
🌅 On the Horizon: A quick look at the developments and events expected to shape the weeks ahead.
👉 Feb. 26 - Harvard Business Review Strategy Summit: Build your transformation playbook for the AI era.
👉 Mar 12–18, 2026 — SXSW 2026, Austin, TX
👉 Mar 30–31, 2026 — IAPP Global Privacy Summit, Washington DC
👉 Apr 6–9, 2026 — HumanX 2026, San Francisco, CA
👉 Apr. 10 — Ethical AI: Leadership and Governance (Virtual)
And finally, if you like what you are reading, please share this newsletter with your networks and encourage them to sign up. ✍️ 🆙 And/or, give me a shout out on LinkedIn.
Till next time,
BC
